University of Colorado researchers have discovered that H3K36 methylation serves as the crucial “switch” controlling intestinal cell regeneration. This biochemical process within the H3 histone protein determines when normal intestinal cells transform into regenerative stem cells following injury.
The findings, published in Nature Cell Biology, have profound implications for colorectal cancer treatment, particularly cancers exhibiting regenerative signatures. Conditions like inflammatory bowel disease, which increase cancer risk through repetitive injury, may benefit directly from therapies targeting this mechanism.
Additionally, this discovery could help address resistance to chemotherapy and radiation, as cells in the regenerative state show increased treatment resilience. Understanding how to manipulate this cellular transformation opens possibilities for drug development, disease modeling, and potentially transplantation therapies.
While researchers emphasize this represents just the beginning of investigation, this fundamental epigenetic mechanism promises new approaches for treating intestinal conditions and cancer.
